Lonquex (lipegfilgrastim)
- Region
- 🇪🇺 EU
- Active substance
- lipegfilgrastim
- Company
- Teva B.V.
- Status
- Authorised
- CHMP opinion
- Thu 30 May 2013
- EU approval
- Thu 25 Jul 2013
- Application
- EMEA/H/C/002556
- ATC
- L03AA14
- Official record
- www.ema.europa.eu
Indication
Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Regulatory milestones
No milestones recorded in the last year.
Follow Lonquex
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.